Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.

doi:10.1016/J.EJPHAR.2005.02.051

Paper

DOI: 10.1016/J.EJPHAR.2005.02.051

Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.

Published May 16, 2005 · Y. Tadori, T. Miwa, K. Tottori

European journal of pharmacology

Q1 SJR score

Citations

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro Study

Highly Cited

Study Snapshot

Aripiprazole has the lowest intrinsic activities at human dopamine D2 receptors, making it a unique antipsychotic agent that effectively treats both positive and negative symptoms of schizophrenia.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Full text analysis coming soon...

References

DOI: 10.1016/S0920-9964(03)00050-1

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

Aripiprazole shows a favorable safety and tolerability profile with low potential for akathisia, extrapyramidal syndrome, and somnolence, potentially offering benefits in schizophrenia treatment.

2003·468citations·S. Marder et al.·Schizophrenia Research

Schizophrenia Research

DOI: 10.1073/pnas.0730708100

Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites

D2S and D2L dopamine receptor isoforms play distinct roles in presynaptic and postsynaptic dopaminergic transmission, respectively.

2003·203citations·N. Lindgren et al.·Proceedings of the National Academy of Sciences of the United States of America

Proceedings of the National Academy of Sciences of the United States of America

DOI: 10.1016/S0893-133X(02)00367-6

Dopamine D2 Receptor-Mediated Inhibition of Dopaminergic Neurons in Mice Lacking D2L Receptors

D2S receptors are the main autoreceptors of central dopaminergic neurons, suggesting potential therapeutic strategies for neuropsychiatric disorders with minimal side-effects.

2002·80citations·D. Centonze et al.·Neuropsychopharmacology

Neuropsychopharmacology

DOI: 10.1124/jpet.102.039867

Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes

Antiparkinson agents show marked heterogeneity in binding profiles, with some showing high affinity for multiple serotonergic and hD5 receptors, while others show low affinity for these receptors.

2002·492citations·M. Millan et al.·Journal of Pharmacology and Experimental Therapeutics

Journal of Pharmacology and Experimental Therapeutics

DOI: 10.1124/jpet.102.039883

Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes

Antiparkinson agents show different patterns of agonist and antagonist properties at various serotonin receptor subtypes, with some showing potent effects at specific receptors.

2002·191citations·A. Newman-Tancredi et al.·Journal of Pharmacology and Experimental Therapeutics

Journal of Pharmacology and Experimental Therapeutics

Citations

DOI: 10.4103/abr.abr_314_21

Evaluation of the Effect of Aripiprazole Supplementation in the Prevention of Delirium in Patients Admitted to the General Intensive Care Unit

Aripiprazole supplementation does not significantly reduce the risk of delirium in patients admitted to the intensive care unit, but may shorten their hospital stay.

2023·0citations·Mehranoosh Nouri et al.·Advanced Biomedical Research

Advanced Biomedical Research

DOI: 10.1111/fcp.12812

Receptor density influences the recruitment bias of aripiprazole and brexpiprazole at the dopamine D2L receptor

High dopamine D2 receptor expression levels influence the recruitment bias of antipsychotics like aripiprazole and brexpiprazole, but not cariprazine, suggesting changes in receptor expression levels could impact their functional response in psychiatry.

2022·2citations·Mattia Ferraiolo et al.·Fundamental & Clinical Pharmacology

Fundamental & Clinical Pharmacology

DOI: 10.1192/bja.2021.49

Partial agonists of dopamine receptors: mechanisms and clinical effects of aripiprazole, brexpiprazole and cariprazine

Aripiprazole, brexpiprazole, and cariprazine are novel antipsychotics with moderate efficacy in schizophrenia, low risk of Parkinsonism or hyperprolactinaemia, and modest weight increases.

2021·7citations·J. Cookson et al.·BJPsych Advances

BJPsych Advances

DOI: 10.1002/npr2.12180

Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole

Otsuka Pharmaceutical Co., Ltd. successfully developed the dopamine D2 receptor partial agonists aripiprazole and brexpiprazole, which are now approved for schizophrenia, major depressive disorder, and irritability associated with autistic disorder.

2021·27citations·T. Kikuchi et al.·Neuropsychopharmacology Reports

Neuropsychopharmacology Reports

DOI: 10.1080/00498254.2021.1890275

Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human

Brexpiprazole has a simple pharmacokinetic profile with good metabolic stability, linear kinetics, and no significant species differences in metabolism or tissue distribution.

2021·12citations·H. Sasabe et al.·Xenobiotica

Xenobiotica